Management Strategies for Xerostomia in Patients with Sjögren’s Syndrome: A Comprehensive Review

ABSTRACT

Xerostomia, commonly known as dry mouth, is a significant complication in patients with Sjögren’s syndrome (SS), an autoimmune disorder primarily affecting the salivary glands. This comprehensive review discusses the various management strategies available to alleviate xerostomia symptoms, including pharmacological and non-pharmacological approaches. Pharmacological treatments, such as cholinergic agents (pilocarpine and cevimeline), have shown effectiveness in stimulating salivary secretion, while topical therapies, like saliva substitutes, provide temporary relief. Non-pharmacological methods, including salivary gland stimulation through chewing gum and dietary modifications, offer additional symptom control. Emerging therapies, such as gene and stem cell therapy, hold promise for future treatment. A multimodal approach tailored to the individual needs of the patient is essential for the optimal management of xerostomia in SS, ultimately improving patients’ quality of life. The review highlights the importance of ongoing research into novel therapeutic approaches to enhance treatment outcomes.

INTRODUCTION

Xerostomia, or dry mouth, is a prominent symptom of Sjögren’s syndrome (SS), an autoimmune disorder primarily affecting the salivary and lacrimal glands, leading to their dysfunction. This condition is often debilitating for patients, affecting oral health, comfort, and overall quality of life. In addition to the characteristic dry mouth, patients with SS may experience dental decay, oral infections, and difficulty speaking and swallowing, further complicating the management of this disorder. As a result, understanding and implementing effective management strategies are essential for improving the quality of life of affected individuals.[1,2,3,4,5]

This article aims to comprehensively review the various strategies available for managing xerostomia in patients with SS, focusing on pharmacological, non-pharmacological, and emerging therapeutic approaches.

Pathophysiology of xerostomia in Sjögren’s syndrome

Xerostomia in SS is a consequence of lymphocytic infiltration of the salivary glands, leading to decreased glandular function and secretion of saliva. This dysfunction results in a reduction in salivary flow and an altered composition of saliva, further exacerbating oral dryness and related complications. The damage to the salivary glands in SS is primarily immune-mediated, with the infiltration of CD4 + T-cells and B-cells into the glands, resulting in the destruction of glandular tissues and a chronic decrease in salivary output.[1]

Management strategies

Pharmacological approaches

Saliva stimulants

Cholinergic agents, such as pilocarpine and cevimeline, are commonly used to stimulate saliva production in patients with xerostomia due to SS. These medications work by stimulating muscarinic receptors in the salivary glands, thereby enhancing saliva secretion. Pilocarpine is administered in 5 mg doses, typically four times daily, while cevimeline is administered in 30 mg doses three times daily. Both drugs have demonstrated efficacy in improving salivary flow and alleviating symptoms of dry mouth.[2,3]

However, side effects such as sweating, gastrointestinal disturbances, and cardiovascular concerns may limit their use in some patients. As a result, patients should be monitored for adverse effects, especially those with pre-existing comorbidities.

Topical treatments and Saliva substitutes

Topical treatments, including saliva substitutes and mouth rinses, are widely used as supportive therapies for managing xerostomia. Saliva substitutes typically contain agents such as carboxymethylcellulose, glycerin, or mucin to provide lubrication and moisturization to the oral cavity.[4] These agents aim to mimic natural saliva’s functions, offering temporary relief from dryness. Recent advancements in saliva substitutes include those that incorporate polymers and other bioadhesive materials to enhance retention in the oral cavity and improve patient comfort.[5]

Artificial saliva substitutes, although helpful in relieving symptoms, do not stimulate saliva production and require frequent reapplication. They are often used in combination with other treatment modalities to optimize symptom control.

Immunomodulatory therapy

Given the autoimmune nature of SS, immunosuppressive therapies have been explored to manage xerostomia. Hydroxychloroquine, commonly used to treat systemic lupus erythematosus and rheumatoid arthritis, has been investigated for its potential benefits in SS. Some studies suggest that hydroxychloroquine may improve glandular function and reduce symptoms of dry mouth, although its efficacy in this regard remains debated.[6]

Biologic agents, particularly those targeting B-cells (e.g., rituximab), have also been evaluated in the treatment of SS. Rituximab has been shown to improve salivary gland function in some patients with SS, potentially offering a new avenue for managing xerostomia.[7]

Non-pharmacological approaches

Salivary Gland stimulation

Mechanical stimulation of the salivary glands through chewing gum or lozenges is a simple and effective method for enhancing saliva production. Sugar-free chewing gum, particularly that containing xylitol, can stimulate residual salivary function in patients with xerostomia.[8] The act of chewing increases salivary flow, which provides temporary relief from oral dryness. Xylitol has additional benefits for dental health, as it reduces the risk of dental caries.

Dietary modifications and hydration

Maintaining adequate hydration is essential for patients with xerostomia. Patients are encouraged to sip water regularly throughout the day to keep the oral cavity moist. In addition, it is recommended to avoid caffeinated and alcoholic beverages, which can exacerbate dryness. Consuming foods with high water content, such as fruits and vegetables, can also help maintain moisture in the mouth.[9]

Acupuncture and alternative therapies

Acupuncture has gained attention as an alternative therapy for managing xerostomia in patients with SS. Studies have shown that acupuncture may stimulate salivary flow and improve symptoms of dry mouth in some patients, although the mechanism behind this effect is not fully understood.[10] Other complementary therapies, such as herbal treatments, have also been explored, but their efficacy remains inconclusive.

Emerging therapeutic approaches

Gene therapy

Gene therapy is an emerging area of research in the management of xerostomia, particularly in cases where salivary gland function is severely impaired. Experimental approaches involve the use of viral vectors to deliver therapeutic genes to the salivary glands, promoting regeneration and restoration of glandular function. While still in the early stages of development, gene therapy holds promise for patients with severe glandular damage due to SS.[7]

Stem cell therapy

Stem cell therapy is a novel approach being investigated for its potential to regenerate damaged salivary glands in patients with xerostomia. Early studies in animal models have shown promising results, with stem cell-based treatments leading to improved salivary gland function and enhanced tissue repair. Although human trials are needed, stem cell therapy could offer a long-term solution for xerostomia in the future.[8]

Biomaterials and advanced polymeric systems

Advancements in biomaterials and polymer science have led to the development of novel saliva substitutes that not only mimic the physical properties of natural saliva but also provide long-lasting relief. These materials are designed to adhere to the oral mucosa, offering sustained moisturization and lubrication. Future developments in this area may lead to improved therapeutic options for patients with severe xerostomia.[6]

CONCLUSION

Xerostomia remains a challenging symptom to manage in patients with SS due to the underlying autoimmune dysfunction of the salivary glands. While several pharmacological and non-pharmacological strategies exist to alleviate symptoms, a multimodal approach that includes saliva stimulants, topical treatments, and lifestyle modifications is often necessary. Emerging therapies, such as gene and stem cell therapy, offer hope for future advancements in the management of xerostomia, potentially leading to more effective and long-lasting solutions. In the meantime, individualizing treatment based on patients’ needs and preferences is essential for optimizing care and improving quality of life.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.